Discussion
The U.S. Food and Drug Administration (FDA) has granted fast-track designation to CK0803, an experimental T-cell therapy from Cellenkos that’s currently in Phase 1 clinical testing for people with amyotrophic lateral sclerosis (ALS). The designation aims to accelerate the clinical development and regulatory review of new treatments that…